Reports
Sale
Global Psoriasis Treatment Market Share, Trends, Forecast: By Diagnosis Method: Blood Tests, Skin Prick Test, Others; By Treatment Type; By Type; By Therapy Type; By Route of Administration; By Drug Type; By Population Type; By Treatment Channel; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Global Psoriasis Treatment Market Outlook
The global psoriasis treatment market value was USD 26.13 billion in 2023, driven by the increasing prevalence of psoriasis across the globe. The market size is anticipated to grow at a CAGR of 9.23% during the forecast period of 2024-2032 to achieve a value of USD 57.84 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The Increasing Prevalence of Psoriasis Disease is Augmenting the Market Growth of Psoriasis Treatment
The global market for psoriasis treatment is being driven by increasing incidences of psoriasis due to certain genetic or environmental factors, thereby augmenting the demand for effective treatment and hence stimulating the growth of the market.
According to the World Health Organisation, the reported prevalence of psoriasis in countries range from 0.09% to 11.4%, making it a serious global problem. A combination of topical and systematic therapies to reduce the effects of psoriasis is a lifelong treatment aimed at remission, has been driving the growth of the market. Thus, robust investments towards the development of advanced treatment methods to control the spread of psoriasis disease are aiding the market growth.
Psoriasis Treatment: Market Segmentation
Psoriasis refers to a common inflammatory condition in which skin cells build up and form scales and itchy, dry patches. Treatment such as topical ointments, light therapy, and medication aims to remove scales and stop the robust growth of skin cells.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
On the basis of drug class, the market can be divided into:
- TNF Inhibitors
- Interleukins
- Others
Based on type, the market can be categorised into:
- Plaque Psoriasis
- Psoriatic Arthritis
- Others
The market, based on route of administration, can be segmented into:
- Oral
- Parenteral
- Topical
On the basis of distribution channel, the market can be classified into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
The EMR report looks into the regional markets of psoriasis treatment like North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Robust Research and Development (R&D) for the Development of Effective Treatments to Propel the Market Growth
The growth in the global market for psoriasis treatment is expected to be determined by the rising awareness regarding the negative impact of the disease. Since the exact reason for the psoriasis disease is unknown, robust research and development (R&D) about the cause, potential effects, and effective treatments is expected to have a significant influence over the growth of the market. In addition to this, favourable government measures such as reimbursement schemes, subsidised treatments, and other thoughtful measures are also expected to boost the market growth. Moreover, the market is further projected to grow due to the presence of an extensive distribution channel, including retail and hospital pharmacies and online channels, which aid in the easy availability of the medication. Hence, these factors are anticipated to bolster the overall market growth of psoriasis treatment.
Key Industry Players in the Global Psoriasis Treatment Market
The report presents a detailed analysis of the following key players in the global psoriasis treatment market, looking into their capacity, market share, and latest developments like capacity expansions, plant turnabouts and mergers and acquisitions:
- AbbVie Inc.
- Novartis AG
- Johnson and Johnson Services, Inc.
- Pfizer Inc.
- Merc and Co., Inc.
- Others
The comprehensive report looks at the micro and macro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of the Porter’s Five Forces Model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnosis Method |
|
| Breakup by Treatment Type |
|
| Breakup by Type |
|
| Breakup by Therapy Type |
|
| Breakup by Route of Administration |
|
| Breakup by Drug Type |
|
| Breakup by Population Type |
|
| Breakup by Treatment Channel |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Psoriasis Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Psoriasis Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Psoriasis Epidemiology (2016-2031)
5.3 Europe Psoriasis Epidemiology (2016-2031)
5.4 Asia-Pacific Psoriasis Epidemiology (2016-2031)
5.5 Latin America Psoriasis Epidemiology (2016-2031)
5.6 Middle East & Africa Psoriasis Epidemiology (2016-2031)
6 Global Psoriasis Treatment Market Overview
6.1 Global Psoriasis Treatment Market Historical Value (2017-2023)
6.2 Global Psoriasis Treatment Market Forecast Value (2024-2032)
7 Global Psoriasis Treatment Market Landscape
7.1 Psoriasis Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Psoriasis Treatment: Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Psoriasis Type
7.2.3 Analysis by Therapy Type
7.2.4 Analysis by Distribution Channel
7.2.5 Analysis by End User
8 Psoriasis Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Psoriasis Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Psoriasis Treatment Market Segmentation
11.1 Global Psoriasis Treatment Market by Diagnosis Method
11.1.1 Market Overview
11.1.2 Blood Tests
11.1.3 Skin Prick Test
11.1.4 Patch Test
11.1.5 Biopsy
11.1.6 Others
11.2 Global Psoriasis Treatment Market by Treatment Type
11.2.1 Market Overview
11.2.2 Biologics Drugs
11.2.2.1 Apremilast
11.2.2.2 Atanercept
11.2.2.3 Infliximab
11.2.2.4 Adalimumab
11.2.2.5 Ustekinumab
11.2.2.6 Secukinumab
11.2.2.7 Ixekizumab
11.2.2.8 Guselkumab
11.2.2.9 Tildrakizumab
11.2.2.10 Certolizumab
11.2.2.11 Others
11.2.3 Systemic Drugs
11.2.3.1 Methotrexate
11.2.3.2 Soriatane
11.2.3.3 Otezla
11.2.3.4 Sotyktu
11.2.3.5 Cyclosporin
11.2.3.6 Others
11.2.4 Phototherapy
11.2.4.1 Ultraviolet B (UVB)
11.2.5 Topical Drugs
11.2.5.1 Calcipotriene
11.2.5.2 Tazarotene
11.2.5.3 Calcineurin inhibitors
11.2.5.4 Roflumilast
11.2.5.5 Salicylic acid
11.2.5.6 Others
11.2.6 Others
11.3 Global Psoriasis Treatment Market by Type
11.3.1 Market Overview
11.3.2 Plaque Psoriasis
11.3.3 Psoriatic Arthritis
11.3.4 Others
11.4 Global Psoriasis Treatment Market by Therapy Type
11.4.1 Market Overview
11.4.2 Monotherapy
11.4.3 Combination Therapy
11.5 Global Psoriasis Treatment Market by Route of Administration
11.5.1 Market Overview
11.5.2 Oral
11.5.2.1 Tablets
11.5.2.2 Capsules
11.5.3 Parentals
11.5.3.1 Intravenous
11.5.3.2 Intramuscular
11.5.4 Topicals
11.5.5 Others
11.6 Global Psoriasis Treatment Market by Drug Type
11.6.1 Market Overview
11.6.2 Over the Counter
11.6.3 Prescription
11.6.3.1 Branded
11.6.3.2 Generics
11.7 Global Psoriasis Treatment Market by Population Type
11.7.1 Market Overview
11.7.2 Childs
11.7.3 Adults
11.7.3.1 Male
11.7.3.2 Female
11.7.4 Geriatrics
11.7.4.1 Male
11.7.4.2 Female
11.8 Global Psoriasis Treatment Market by Treatment Channel
11.8.1 Market Overview
11.8.2 Public
11.8.3 Private
11.9 Global Psoriasis Treatment Market by End User
11.9.1 Market Overview
11.9.2 Hospitals
11.9.3 Specialty Clinics
11.9.4 Homecare Settings
11.9.5 Others
11.10 Global Psoriasis Treatment Market by Distribution Channel
11.10.1 Market Overview
11.10.2 Hospital Pharmacy
11.10.3 Retail Pharmacy
11.10.4 Online Pharmacy
11.10.5 Others
11.11 Global Psoriasis Treatment Market by Region
11.11.1 Market Overview
11.11.2 North America
11.11.3 Europe
11.11.4 Asia Pacific
11.11.5 Latin America
11.11.6 Middle East and Africa
12 North America Psoriasis Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Psoriasis Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Psoriasis Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Psoriasis Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Psoriasis Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Pfizer Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Abbvie Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Novartis AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Amgen Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Boehringer Ingelheim International GmbH.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Merck & Co Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Sun Pharmaceutical Industries Ltd.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Teva Pharmaceuticals Industries Ltd.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 AstraZeneca
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Ampio Pharmaceuticals Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Eli Lilly and Company
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Novartis International AG
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Sun Pharmaceuticals Industries Ltd.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Stiefel Laboratories
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 UCB S.A.
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
23.16 LEO Pharma
23.16.1 Financial Analysis
23.16.2 Product Portfolio
23.16.3 Demographic Reach and Achievements
23.16.4 Mergers and Acquisitions
23.16.5 Certifications
23.17 Cipla Inc.
23.17.1 Financial Analysis
23.17.2 Product Portfolio
23.17.3 Demographic Reach and Achievements
23.17.4 Mergers and Acquisitions
23.17.5 Certifications
23.18 Rowan Bioceuticals
23.18.1 Financial Analysis
23.18.2 Product Portfolio
23.18.3 Demographic Reach and Achievements
23.18.4 Mergers and Acquisitions
23.18.5 Certifications
23.19 Glenmark Pharmaceuticals
23.19.1 Financial Analysis
23.19.2 Product Portfolio
23.19.3 Demographic Reach and Achievements
23.19.4 Mergers and Acquisitions
23.19.5 Certifications
23.20 Win-Medicare Pvt. Ltd.
23.20.1 Financial Analysis
23.20.2 Product Portfolio
23.20.3 Demographic Reach and Achievements
23.20.4 Mergers and Acquisitions
23.20.5 Certifications
23.21 Sanofi S.A.
23.21.1 Financial Analysis
23.21.2 Product Portfolio
23.21.3 Demographic Reach and Achievements
23.21.4 Mergers and Acquisitions
23.21.5 Certifications
24 Psoriasis Treatment Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The psoriasis treatment market was valued at USD 26.13 billion in 2023.
The market is expected to grow at a CAGR of 9.23 % from 2024 to 2032 to reach a value of USD 57.84 billion by 2032.
The increasing prevalence of psoriasis disease is augmenting the demand for an effective treatment, which is propelling the overall growth of the market.
The market is expected to be driven by the robust research and development (R&D) towards the development of an effective treatment of psoriasis.
The major regional markets for psoriasis treatment are North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.
The major drug classes of psoriasis treatment are TNF inhibitors and interleukins, among others.
The different types of psoriasis treatment are plaque psoriasis, and psoriatic arthritis, among others.
The market, based on route of administration, can be segmented into oral, parenteral, and topical.
The significant distribution channels of psoriasis treatment are hospital pharmacies, retail pharmacies, and online pharmacies.
The major players in the industry are AbbVie Inc., Novartis AG, Johnson and Johnson Services, Inc., Pfizer Inc., and Merc and Co., Inc., among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5999
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 7999
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9999
$5999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER